Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia
Open Access
- 17 April 2007
- journal article
- Published by Springer Nature in BMC Women's Health
- Vol. 7 (1) , 6
Abstract
Limited data are available regarding the cost-effectiveness of preventative therapies for postmenopausal women with osteopenia. The objective of the present study was to evaluate the cost-effectiveness of raloxifene, alendronate and conservative care in this population.Keywords
This publication has 58 references indexed in Scilit:
- Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease OutcomesThe NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 TrialJAMA, 2006
- The population burden of fractures originates in women with osteopenia, not osteoporosisOsteoporosis International, 2006
- Alendronate and Vertebral Fracture RiskMayo Clinic Proceedings, 2005
- Alendronate and Vertebral Fracture RiskMayo Clinic Proceedings, 2005
- Bone Mineral Density Thresholds for Pharmacological Intervention to Prevent FracturesArchives of internal medicine (1960), 2004
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Cost Effectiveness of Treatment Options in Advanced Breast Cancer in the UKPharmacoEconomics, 2001
- Health-Related Quality of Life in Postmenopausal Women With Low BMD With or Without Prevalent Vertebral FracturesJournal of Bone and Mineral Research, 2000
- A Cost-Utility Analysis of Second-Line Chemotherapy in Metastatic Breast CancerPharmacoEconomics, 1996
- Projecting Individualized Probabilities of Developing Breast Cancer for White Females Who Are Being Examined AnnuallyJNCI: Journal of the National Cancer Institute, 1989